Clinical Trial Detail

NCT ID NCT02475213
Title Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors MacroGenics
Indications

head and neck squamous cell carcinoma

melanoma

lung non-small cell carcinoma

Therapies

MGA271 + Pembrolizumab

Age Groups: adult

No variant requirements are available.